AI Maverick Intel Inc. (OTC: AIMV) has entered into a Right of First Refusal Agreement with HEAL Group Holdings Inc., providing the artificial intelligence company with exclusive access to evaluate and potentially acquire healthcare technology assets. The agreement, effective February 11, 2026, grants AIMV the ability to review and match third-party offers for specific HEAL assets or business units under predetermined conditions.
The strategic arrangement covers HEAL's portfolio of AI-driven healthcare technology and services operating in more than six countries. In exchange for this exclusive access, AI Maverick Intel will issue 120,000,000 common shares to HEAL at a deemed price of $0.02 per share, representing total consideration of $2.4 million. The agreement remains in place for three years unless terminated earlier by mutual agreement between the parties.
This development positions AI Maverick Intel at the intersection of artificial intelligence and healthcare technology, two sectors experiencing significant growth and transformation. The company, which focuses on identifying opportunities where artificial intelligence, data platforms, and emerging technology-enabled industries converge, now has a structured pathway to potentially expand its healthcare technology portfolio through strategic acquisitions.
The right of first refusal mechanism provides AI Maverick Intel with a competitive advantage in the healthcare technology acquisition landscape. By securing this agreement, the company can evaluate HEAL's assets as they become available for potential sale, matching any third-party offers that emerge during the three-year term. This approach allows for strategic portfolio expansion while maintaining financial flexibility.
For business and technology leaders, this agreement represents a strategic move in the competitive healthcare AI sector. The arrangement demonstrates how companies are structuring innovative agreements to secure access to valuable technology assets without immediate full acquisition commitments. The healthcare technology market, particularly segments leveraging artificial intelligence for improved patient outcomes and operational efficiency, continues to attract significant investment and strategic interest.
The latest news and updates relating to AIMV are available in the company's newsroom at http://ibn.fm/AIMV. The full press release detailing this agreement can be viewed at https://ibn.fm/7LS0i. This development comes as healthcare systems worldwide increasingly adopt artificial intelligence solutions to address challenges ranging from diagnostic accuracy to operational efficiency and personalized treatment approaches.
The three-year term of the agreement provides AI Maverick Intel with an extended window to evaluate market conditions and HEAL's asset performance before making acquisition decisions. This timing aligns with broader industry trends showing accelerated adoption of healthcare AI solutions across global markets. The multi-country reach of HEAL's operations further expands the potential geographic footprint of any future acquisitions through this agreement.
For investors and industry observers, this right of first refusal arrangement represents a strategic positioning play in the competitive healthcare technology landscape. It provides AI Maverick Intel with privileged access to acquisition opportunities while allowing the company to maintain capital allocation flexibility during the evaluation period. The structure of the agreement, involving share issuance rather than immediate cash payment, represents an innovative approach to securing strategic advantages in technology-driven industries.
